Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BWAYNASDAQ:CODXNASDAQ:PAVMNASDAQ:SSKN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBWAYBrainsWay$8.83+1.4%$9.08$5.13▼$11.79$166.64M1.2570,520 shs47,048 shsCODXCo-Diagnostics$0.34+0.5%$0.39$0.28▼$2.23$11.47M0.84192,397 shs67,312 shsPAVMPAVmed$0.71+3.6%$0.71$0.55▼$2.35$11.66M1.11116,775 shs109,793 shsSSKNSTRATA Skin Sciences$2.54+3.3%$2.62$2.10▼$4.70$10.59M0.6812,738 shs4,896 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBWAYBrainsWay+1.38%+1.38%+4.37%-18.77%+65.67%CODXCo-Diagnostics+0.50%-2.98%-7.43%-49.76%-69.23%PAVMPAVmed+5.78%-8.29%+4.17%-1.78%-66.69%SSKNSTRATA Skin Sciences+3.25%-5.22%-2.53%-9.77%-32.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBWAYBrainsWay3.3124 of 5 stars3.53.00.00.03.80.81.9CODXCo-Diagnostics4.4212 of 5 stars3.55.00.04.42.60.01.3PAVMPAVmed4.5497 of 5 stars3.85.00.04.33.30.80.6SSKNSTRATA Skin Sciences3.2479 of 5 stars3.55.00.00.01.91.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBWAYBrainsWay 3.00Buy$14.2561.38% UpsideCODXCo-Diagnostics 3.00Buy$5.501,510.07% UpsidePAVMPAVmed 3.50Strong Buy$19.502,661.26% UpsideSSKNSTRATA Skin Sciences 3.00Buy$6.00136.22% UpsideCurrent Analyst Ratings BreakdownLatest PAVM, SSKN, BWAY, and CODX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2025CODXCo-DiagnosticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025CODXCo-DiagnosticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.004/21/2025PAVMPAVmedAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $19.503/28/2025CODXCo-DiagnosticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$1.50 ➝ $1.003/12/2025BWAYBrainsWayHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.002/27/2025SSKNSTRATA Skin SciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBWAYBrainsWay$41.02M4.06N/AN/A$2.50 per share3.53CODXCo-Diagnostics$3.92M2.93N/AN/A$2.81 per share0.12PAVMPAVmed$3.00M4.03N/AN/A($3.35) per share-0.21SSKNSTRATA Skin Sciences$33.56M0.32N/AN/A$3.65 per share0.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBWAYBrainsWay-$4.20M$0.1788.3155.19N/A3.88%3.52%2.26%5/13/2025 (Estimated)CODXCo-Diagnostics-$35.33M-$1.24N/AN/AN/A-563.93%-54.94%-49.28%N/APAVMPAVmed-$64.18M-$2.25N/AN/AN/A602.97%N/A-92.36%5/15/2025 (Estimated)SSKNSTRATA Skin Sciences-$10.83M-$2.69N/AN/AN/A-28.72%-69.33%-17.55%5/14/2025 (Estimated)Latest PAVM, SSKN, BWAY, and CODX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PAVMPAVmed-$0.40N/AN/AN/A$0.02 millionN/A5/14/2025Q1 2025SSKNSTRATA Skin Sciences-$0.56N/AN/AN/A$7.28 millionN/A5/13/2025Q1 2025BWAYBrainsWay$0.02N/AN/AN/A$11.45 millionN/A5/8/2025Q1 2025CODXCo-Diagnostics-$0.33-$0.24+$0.09-$0.24$0.38 million$0.05 million3/27/2025Q4 2024CODXCo-Diagnostics-$0.34-$0.36-$0.02-$0.36$0.38 million$0.15 million3/27/2025Q4 2024SSKNSTRATA Skin Sciences-$0.40-$1.13-$0.73-$1.13$9.03 million$33.56 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBWAYBrainsWayN/AN/AN/AN/AN/ACODXCo-DiagnosticsN/AN/AN/AN/AN/APAVMPAVmedN/AN/AN/AN/AN/ASSKNSTRATA Skin SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBWAYBrainsWayN/A4.524.23CODXCo-DiagnosticsN/A6.926.70PAVMPAVmedN/A0.060.06SSKNSTRATA Skin Sciences1.621.130.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBWAYBrainsWay30.11%CODXCo-Diagnostics14.99%PAVMPAVmed19.93%SSKNSTRATA Skin Sciences32.43%Insider OwnershipCompanyInsider OwnershipBWAYBrainsWay19.00%CODXCo-Diagnostics8.40%PAVMPAVmed11.30%SSKNSTRATA Skin Sciences39.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBWAYBrainsWay12018.87 million15.24 millionNot OptionableCODXCo-Diagnostics10033.57 million29.98 millionOptionablePAVMPAVmed9017.09 million9.82 millionOptionableSSKNSTRATA Skin Sciences1204.17 million2.54 millionNot OptionablePAVM, SSKN, BWAY, and CODX HeadlinesRecent News About These CompaniesSTRATA Skin Sciences to Join D. Boral Capital’s Inaugural Global Conference in NYCMay 11 at 10:58 PM | msn.comSTRATA Skin Sciences to Announce Q1 2025 Financial Results and Host Investor CallMay 11 at 7:05 AM | msn.comSTRATA Skin Sciences to Report First Quarter 2025 Financial Results on May 14, 2025 and Provide Corporate UpdateMay 9, 2025 | seekingalpha.comSTRATA Skin Sciences to Participate in the D. Boral Capital Inaugural Global ConferenceMay 8, 2025 | globenewswire.comSTRATA Skin Sciences to Report First Quarter 2025 Financial Results on May 14, 2025 and Provide Corporate UpdateMay 7, 2025 | globenewswire.comStrata Skin Sciences price target lowered to $14 from $16 at LadenburgMarch 31, 2025 | markets.businessinsider.comEarnings call transcript: STRATA Skin Sciences Q4 2024 revenue rises 10%March 29, 2025 | uk.investing.comSTRATA Skin Sciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS LagsMarch 29, 2025 | finance.yahoo.comSTRATA SKIN SCIENCES Earnings Results: $SSKN Reports Quarterly EarningsMarch 29, 2025 | nasdaq.comStrata Skin Sciences (SSKN) Gets a Buy from Maxim GroupMarch 29, 2025 | markets.businessinsider.comSTRATA Skin Sciences, Inc. (NASDAQ:SSKN) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | insidermonkey.comSTRATA Skin Sciences Reports Strong Q4 Growth and Strategic ProgressMarch 29, 2025 | msn.comQ4 2024 STRATA Skin Sciences Inc Earnings CallMarch 28, 2025 | finance.yahoo.comStrata Skin Sciences reports Q4 EPS ($1.18), consensus (40c)March 28, 2025 | markets.businessinsider.comSTRATA Skin Sciences, Inc.: STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Corporate UpdateMarch 28, 2025 | finanznachrichten.deSTRATA Skin Sciences, Inc. (SSKN) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comSTRATA Skin Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Corporate UpdateMarch 27, 2025 | globenewswire.comSTRATA SKIN SCIENCES Earnings Preview: Recent $SSKN Insider Trading, Hedge Fund Activity, and MoreMarch 25, 2025 | nasdaq.comSTRATA Skin Sciences to Announce Year-End Financial ResultsMarch 23, 2025 | msn.comStrata Skin Sciences highlights clinical study from Japan on Excimer Laser techMarch 21, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePAVM, SSKN, BWAY, and CODX Company DescriptionsBrainsWay NASDAQ:BWAY$8.83 +0.12 (+1.38%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$9.07 +0.24 (+2.72%) As of 05/12/2025 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.Co-Diagnostics NASDAQ:CODX$0.34 +0.00 (+0.50%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$0.34 +0.00 (+0.70%) As of 05/12/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.PAVmed NASDAQ:PAVM$0.71 +0.02 (+3.56%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$0.68 -0.03 (-3.57%) As of 05/12/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.STRATA Skin Sciences NASDAQ:SSKN$2.54 +0.08 (+3.25%) As of 05/12/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company products include XTRAC and Pharos excimer lasers, and VTRAC lamp systems for the treatment systems that are used for the treatment of psoriasis, vitiligo, and other skin conditions. It also offers TheraClear Acne Therapy System for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
